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Abstract
The function of the tumor suppressor RE1 silencing transcription factor (REST) is lost in colon and small cell lung cancers and
is known to induce anchorage-independent growth in human mammary epithelial cells. However, nothing is currently
known about the role of this tumor suppressor in breast cancer. Here, we test the hypothesis that loss of REST function
plays a role in breast cancer. To assay breast tumors for REST function, we developed a 24-gene signature composed of
direct targets of the transcriptional repressor. Using the 24- gene signature, we identified a previously undefined RESTless
breast tumor subtype. Using gene set enrichment analysis, we confirmed the aberrant expression of REST target genes in
the REST–less tumors, including neuronal gene targets of REST that are normally not expressed outside the nervous system.
Examination of REST mRNA identified a truncated splice variant of REST present in the REST–less tumor population, but not
other tumors. Histological analysis of 182 outcome-associated breast tumor tissues also identified a subpopulation of
tumors that lack full-length, functional REST and over-express the neuroendocrine marker and REST target gene
Chromogranin A. Importantly, patients whose tumors were found to be REST–less using either the 24-gene signature or
histology had significantly poorer prognosis and were more than twice as likely to undergo disease recurrence within the
first 3 years after diagnosis. We show here that REST function is lost in breast cancer, at least in part via an alternative
splicing mechanism. Patients with REST–less breast cancer undergo significantly more early disease recurrence than those
with fully functional REST, regardless of estrogen receptor or HER2 status. Importantly, REST status may serve as a predictor
of poor prognosis, helping to untangle the heterogeneity inherent in disease course and response to treatment.
Additionally, the alternative splicing observed in REST–less breast cancer is an attractive therapeutic target.
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Introduction
Identification of tumor suppressors is hampered by the fact that
their loss of function can occur through any one of many
mechanisms including inactivating mutations, aberrant splicing
and copy number aberration. Transcription factor tumor
suppressors control many downstream genes in a given cell;
however, using the absence or presence of a downstream gene as a
proxy for loss of tumor suppressor function is problematic because
each gene is likely to be regulated by multiple transcription factors.
Genome-wide transcription profiling has opened up the possibility
of simultaneously measuring expression levels of multiple, if not
all, downstream target genes of a tumor suppressor. In this report
we describe the generation of such a signature for the tumor
suppressor RE1 Silencing Transcription Factor (REST Enterez
GeneID 5978), also known as Neuron Restrictive Silencing
Factor (NRSF), and the identification of this signature in breast
cancer.
REST was originally isolated from a screen for factors that
confer neuron-restricted gene expression upon neuronal genes
[1,2]. REST represses transcription by binding to the 17–33 base
pair Repressor Element 1 (RE1) found in the regulatory regions of
target genes [3,4]. Around 2,000 genes in the human and mouse
genomes have been identified as direct targets of REST [4,5].
REST represses transcription by recruiting chromatin modifying
enzymes such as histone deacetylases (HDACs) and histone
methyltransferases (HMTs) via the N-terminal and C-terminal
repression domains respectively and possesses a DNA binding
domain (DBD) consisting of 8 zinc fingers[6–10].
Alternative splicing of REST occurs in the mouse brain during
seizures and results in the expression of the truncated splice
variant, REST4 [11]. The inclusion of an alternative exon into the
coding region of REST results in the insertion of a premature stop
codon, generating a truncated protein containing just the N-
terminal repression domain and five of the eight zinc fingers.
REST4 is a poor repressor of transcription because of reduced
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[8].
Splicing of REST mRNA into its REST4 form also occurs in
small cell lung cancer (SCLC), resulting in the overexpression of
REST target genes and imparting a neuroendocrine phenotype on
the cells [12]. Re-expression of functional REST in REST4-
expressing SCLC cells induces apoptosis, suggesting that suppres-
sion of REST function is key to survival of these cells [13]. In an
unbiased tumor suppressor screen, REST loss conferred anchor-
age-independent growth upon immortalized human mammary
epithelial cells [14]. The authors described a truncating point
mutation that eliminates the C-terminal repression domain in
colon cancer, the expression of which was sufficient to induce
anchorage-independent growth. However, no role for REST in
breast cancer was reported.
To determine whether the tumor suppressor REST is lost in
breast cancer, we developed a gene signature-based approach to
screen for loss of REST function by measuring the expression of a
cohort of REST target genes. Using this gene signature as well as
an immuno-histochemical screen, we show here that an aggressive
subset of breast cancers lack functional REST (‘‘REST–less
tumors’’), instead, often expressing the truncated REST splice
variant REST4.
Results
REST expression in BC tumors
Given that loss of REST induces anchorage-independent
growth in mammary epithelial cells, and is lost in colon [14]
and small cell lung cancers [12], we asked whether REST also
plays a role in breast cancer. REST function is regulated at
multiple post-transcriptional levels during differentiation and
disease [15–18] and so we needed a method of detecting a loss
of REST function in a tumor, regardless of the underlying
mechanism responsible for the loss of the tumor suppressor. To
accomplish this, we developed a gene signature comprised of
direct targets of REST repression with which to interrogate tumor
microarray datasets to search for a loss of REST function.
There are approximately 2,000 RE1-bearing genes in the
mouse and human genomes; however, not all of these genes are
repressed by REST in every cell type [19,20]. Therefore, in order
to generate a gene signature with which to interrogate tumor
microarrays for loss of REST function, we first sought to identify a
set of REST target genes that are coordinately up-regulated when
REST function is lost in multiple cell types, including tumorigenic
and non-tumorigenic breast cells. To that end, we stably infected
three disparate cell lines, the non-tumorigenic MCF10a mammary
epithelial cell line, T47D breast cancer line and the unrelated
human embryonic kidney-293 line with lentivirus expressing a
non-targeting control shRNA (shCon) or an anti-REST shRNA
(shREST), which resulted in the robust knockdown of REST
protein (Figure 1A). RNA from shCon and shREST cells was
harvested and subjected to gene expression microarray analysis.
Of those genes that were up-regulated at least twofold upon REST
knockdown, 93 were up-regulated in at least 2 cell lines, and 24 in
all three cell lines (Figure 1B, Table S1). All of the 24 commonly
upregulated genes are either known REST targets or putative
REST targets as defined by the presence of a 17–33 bp REST
binding element (RE1) within 12 kb of the coding region (Table
S1). These genes formed the first iteration of our 24-gene signature
(Figure 1B).
REST function is lost in breast cancer
Using our 24-gene signature, we screened a microarray dataset
containing 129 breast tumors [21] for loss of REST function. In a
subset of tumor samples, we observed a concerted over-expression
of REST target genes, and designated this group as REST–less
(Figure 2A). To find other genes that showed this coordinated
upregulation in REST–less tumors, we screened the microarray
data for transcripts differentially expressed between REST–less
and full-length REST (RESTfl for REST-full-length) expressing
tumors using a random-variance t-test (Figure 2B). Of the 72 genes
whose expression is most closely associated with the putative
REST–less tumors (p,10
27), 63 (87.5%) either contain perfect
consensus RE1 sites, are upregulated two-fold or greater upon
REST knockdown, or were bound by REST in a genome-wide
ChIP-Seq screen performed by Johnson et al. [4] (Table S2),
suggesting that they are direct targets of REST repression. To
determine whether loss of REST function occurs exclusively in
neoplastic mammary tissue, we used the 24-gene signature to
screen 66 non-neoplastic mammary samples, half of which came
from non-tumor bearing normal breast and half of which were
adjacent normal stroma from a tumor-bearing breast [22]. We
found no evidence of the 24-gene signature in any of the 66
stromal samples (Figure 2C), suggesting that the carcinoma cells
carry this defect in tumors.
To further test whether REST function was lost in REST–less
tumors, we performed Gene Set Enrichment Analysis (GSEA) on
the above breast tumors using the 24-gene signature (Figure 3A).
This method compares the expression of a set of experimentally-
defined REST target genes (termed ‘‘S’’) between REST–less and
RESTfl tumors, and assesses the relative enrichment of ‘S’ in
either tumor group. The positive enrichment score obtained from
these analyses, along with the low nominal P-value (p,0.001) and
false discovery rate q-value (FDR q-value,0.001), are indicative of
high level enrichment of REST target gene expression in the
REST–less tumor subset not likely to occur by random chance.
We also tested the gene set identified by the class comparison
analysis (minus the 24-gene signature) using GSEA, and found that
gene set to be strongly enriched in the REST–less tumor subgroup
Author Summary
Breast cancer is a heterogeneous disease, with highly
variable disease outcomes and responses to treatment for
otherwise indistinguishable tumors. Understanding this
heterogeneity holds the key to better determining disease
prognosis and tailoring treatments to the tumors for which
they will be most efficacious. Some of the most successful
work dissecting the differences between histologically
identical tumors with differing disease outcomes has come
from profiling the array of protein-coding transcripts
present in every tumor and dividing the breast cancer
profiles into multiple subtypes of varying aggressiveness.
Importantly, these profiles are now being used in the clinic
to predict disease outcome and plan treatment. Using a
similar molecular-profiling strategy, we have identified a
previously unrecognized subset of breast cancers in which
the tumor suppressor gene REST is lost, which display a
highly aggressive disease course. Intriguingly, we have
traced the loss of the tumor suppressor to the presence of
a variant of the REST protein normally found in the brain
following seizures, which represents a unique and
attractive therapeutic target. Additionally, the gene
signature used to identify REST–less tumors shows no
overlap with the profiles currently used in the clinic to
assess tumor aggressiveness and may be an important
new diagnostic tool.
REST Is Lost in Aggressive Breast Cancer
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genes that are at least two-fold over-expressed across the average
of all three REST-knock-down cell lines (minus the 24-gene
signature). This analysis found that REST–less tumors have a
widespread and statistically significant loss of REST function
(Figure 3C, nominal p-value,0.001, FDR q-value,0.001).
Finally, we performed GSEA using an unbiased list of REST
targets derived from a published ChIPSeq assay performed in a
wholly different cell system, Jurkat T cells (Figure 3D)[4]. This
unprejudiced approach also found that REST–less tumors, with
respect to their RESTfl counterparts, are strongly enriched in the
expression of REST target genes (nominal p-value,0.001, FDR
q-value ,0.01).
REST mRNA levels are not altered in REST–less breast
cancer
We tested the possibility that the abrogation of REST function
may be due to a loss of REST mRNA by comparing transcript
levels in REST–less and RESTfl tumor samples. We saw no
difference in REST transcript levels between the two tumor types
(Figure 4A). Intriguingly, we noticed that REST mRNA levels
were significantly higher in tumors than in normal tissue in three
independent datasets representing over 250 normal and neoplastic
tissue samples (Figure 4B). Furthermore, analysis of REST
transcript levels in an additional 700 samples across multiple
datasets found that REST mRNA levels are unaltered across
tumors of increasing stage, grade, or likelihood to eventually
relapse (Figure 4C).
REST–less tumors show increased levels of the REST
splice variant REST4
Alternative splicing of REST to generate the truncated REST4
variant results in a protein with diminished DNA binding ability
and loss of repressive function, and has been identified in the
nervous system and in SCLC [8,12,23–25]. We therefore asked
whether aberrant REST splicing could explain the loss of REST
function in breast cancer. We were able to obtain RNA from two
REST–less and seven RESTfl tumor samples which we amplified
and interrogated for splicing by Reverse Transcription PCR using
primers flanking the alternative REST4 exon. This analysis
detected high levels of alternative splicing, resulting in the
inclusion of the REST4 exon in REST–less tumors, which could
not be detected in RESTfl tumors (Figure 5A). Selective
amplification of REST4 using a primer placed in the REST4
exon confirmed the presence of the splice variant expression
exclusively in the REST–less tumors (Figure 5A and 5B). Statistical
analysis of these data using Fisher’s exact test suggest that the
presence of REST4 splicing in REST–less tumors alone was
unlikely to have occurred by random chance (p,0.05). These data
demonstrate that REST4 splicing is at least one mechanism by
which full length REST may be lost in breast cancer.
We then used the 24-gene signature to classify the breast tumor
superseries GSE6532 into REST–less and RESTfl tumors and
determined how REST status associated with patient outcome
(Figure 5C) [26]. This analysis shows that REST–less tumors
identified by the REST gene signature manifest an extremely
aggressive disease progression profile (logrank p-value,0.005). In
this dataset, 57% of REST–less tumors recur within 3 years,
compared to 13% of RESTfl tumors. Intriguingly, the REST–less
tumors identified by gene signature show no additional relapse
after 3.5 years, despite high levels of early aggression.
Full-length REST is lost in breast cancer
To determine the frequency of REST protein loss in breast
cancer, we developed an immunohistochemical (IHC) screen using
an antibody directed to the C-terminus of REST (Atlas
Antibodies, Stockholm). To test the specificity of the REST
antibody, we utilized the REST-expressing breast cancer cell line
MCF7. Cells were stably infected with lentiviruses bearing either
non-targeting or REST-targeting shRNA (Figure 6A), then
paraffin-embedded, sectioned and stained for REST C-terminus
(Figure 6B). Non-targeting control shRNA expressing cells showed
strong nuclear REST staining, whereas the REST knockdown
cells show a severely depleted nuclear REST stain, suggesting
specificity for the antibody at levels of REST observed in breast
cancer cells. REST4 and the truncated form of REST identified as
Figure 1. Generation of a 24-gene signature for loss of REST. (A) REST expression was knocked down in HEK, MCF10a, and T47D cell lines
using lentiviral delivery of shRNA targeting REST (shREST) or a control non-targeting shRNA (shControl). Western blot analysis of total protein levels of
REST and beta-actin was performed to confirm knockdown. (B) Microarray analysis of RNA from shREST and shControl cells for each cell type
identified 24 genes (listed) that were up-regulated by at least 2 fold in all three lines.
doi:10.1371/journal.pgen.1000979.g001
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allowing us to identify tumors that lack full-length REST.
Immunohistochemical analysis of 182 breast tumors in a tissue
microarray confirmed the lack of full-length (functional) REST
predicted by the REST4 splicing in 37 (20.3%) tumor samples
(Figure 7B). Additionally, these REST–less tumors showed a
significant enrichment in staining for the ectopic expression of the
REST target gene chromogranin-A (CHGA Enterez GeneID
1113), consistent with a loss of REST repression (Figure 7D,
p,0.001). Importantly, we found that REST–less status correlated
significantly with poor disease-free survival (Figure 8A, p=0.007),
and the average time to relapse for REST–less tumors (14 months)
is less than half of that for RESTfl tumors (35.9 months
p=0.0217). REST–less tumors from this cohort have significantly
Figure 2. The 24-gene signature detects loss of REST function in breast tumors. (A) Hierarchical clustering analysis is performed on gene
expression microarray data from 129 breast cancer tumors (GSE5460) across the 24-gene REST gene signature. Five tumors show a concerted
overexpression of REST target genes, suggesting a loss of REST repression. (B) The expression of genes significantly upregulated in REST–less tumors
(p,10
27) are shown, .85% are either known or putative REST target genes. Arrows indicate tumors from which RNA was available for further
analysis. (C) The REST gene signature is applied 66 samples of normal mammary tissue obtained from mammaplasty and non-tumor stromal samples.
doi:10.1371/journal.pgen.1000979.g002
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several other markers of aggressive, treatment-resistant breast
cancers summarized in Table 1. Patients with REST–less triple
negative (TN) tumors (Estrogen Receptor (ER)/Progesterone
Receptor/HER2-) endure significantly greater disease recurrence
within 2 years than TN/RESTfl patients (50% versus 20%
recurrence, p=0.044, n=32) (Figure 8B). Patients with REST–
less ER+ breast tumors are also more prone to relapse in the first 3
years (Figure 8C, p=0.003, n=135). Strikingly, 100% of disease
recurrence events for patients with REST–less tumors occurred in
the first 36 months, compared to just 61% of all recurrence events
for patients with RESTfl tumors. After 3 years there were no
additional recurrences of REST–less tumors. This suggests that the
loss of REST leads to a more uniquely aggressive disease that is
most likely to recur within 3 years of diagnosis with no observed
occurrence thereafter. Importantly, the IHC staining for REST C-
terminus has the ability to identify tumors that have lost full-length
REST via multiple mechanisms, including REST4 splicing,
ubiquitin-mediated degradation or truncating mutation, as has
been seen in colon cancer [14].
Discussion
In this study we demonstrate that REST function is lost in a fraction
of breast tumors. Loss of REST is defined by either the presence of a
24 gene signature in tumors or by loss of immunohistochemical stain
with a antibody raised to the C-terminus of REST. REST–less tumors
(as determined byeitherIHC or 24-gene signature) are associated with
an aggressive, rapid recurrence prognosis. At this time it is not known
whether REST–less tumors defined by gene signature represent a
subset of those determined to be REST–less by IHC or are a distinct
group of malignancies. Answering this question will allow for the
elucidation of the suite of mechanisms by which REST function can
be lost in breast cancer and will require the analysis of patient cohorts
that have associated patient outcome data, tissue micro-arrays as well
as gene expression data.
A 24-gene signature identifies a distinct cohort of breast
tumors expressing REST4
We have developed two complementary methods of screening
tissue and tumors for their levels of functional REST. For samples
Figure 3. Gene set enrichment analysis of REST–less tumors. Gene Set Enrichment Analysis of the breast tumor dataset GSE5460 shows
induction of REST target genes in REST–less tumors using three separate lists of experimentally defined REST target genes. (A) The ‘‘REST gene
signature’’ 24-gene set comprised of 24 genes consistently upregulated at least two-fold upon REST knockdown in MCF10a, HEK-293 and T47D cell
lines is enriched in REST–less tumors. (B) The list of genes identified in class comparison analysis of REST–less and RESTfl breast tumors are
significantly enriched in REST–less tumors. (C) The ‘‘genes upregulated upon REST knockdown’’ gene set encompasses a wider range of REST targets,
including all genes that were upregulated at least two-fold upon REST knockdown across the average of all three cell lines (minus the 24-gene
signature). This geneset is also enriched in REST–less tumors. The ‘REST ChIPSeq’ gene list that is populated by genes identified as being bound by
REST in Jurkat T-cells using ChIPSeq [4] (minus the 24-gene signature) is also significantly enriched in REST–less tumors.
doi:10.1371/journal.pgen.1000979.g003
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PLoS Genetics | www.plosgenetics.org 5 June 2010 | Volume 6 | Issue 6 | e1000979Figure 4. REST mRNA levels in breast tissue. (A) Mean REST mRNA levels were assessed in REST–less and RESTfl breast tumors from microarray
dataset GSE5460. All error bars represent standard error. (B) Mean REST mRNA levels were compared in normal and tumor tissues across three
independent datasets, all of which show a statistically significant increase in REST mRNA in tumor tissue, compared to normal (p,0.05 Mann Whitney
rank sum test). Aggregate, and individual tumor data are displayed for dataset GDS2250, representing three distinct tumor types in addition to
normal tissue. (C) REST mRNA data is presented from three independent datasets broken down by stratified by stage (E-TABM-158) grade (GSE6532)
and eventual relapse (GSE2034). There is no significant difference in REST mRNA levels across any of these conditions.
doi:10.1371/journal.pgen.1000979.g004
REST Is Lost in Aggressive Breast Cancer
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loss of functional REST. Histological sections can be stained for
the C-terminus of REST in combination with the REST target
gene, chromogranin-A.
It is known that post-transcriptional regulation of REST occurs
during neuronal differentiation and during oncogenic transforma-
tion such that protein levels are significantly reduced in the
absence of altered mRNA levels [15,16,27]. These observations
Figure 5. REST–less breast cancer tumors display high levels of REST4 splicing and poor prognosis. (A) Top panel: PCR primer screens
for REST splicing in selected RNA from tumor samples indicated in Figure 2B: GSM124998, GSM125004, GSM125011, GSM125015, GSM125019,
GSM125027, GSM125050, GSM125080 and GSM125088. Bottom panel: RNA was reverse-transcribed and PCR amplified with primers flanking the REST
alternative intron/exon junction (REST primer set), showing alternative REST splicing only in the REST–less tumors. Additionally, selective PCR
amplification of REST4 from tumor samples (using primers that target the REST4 50 bp exon (REST4 primer set)) demonstrated the presence of REST4
in the REST–less tumors, but not in any of the REST competent tumors. (B) Quantitative real-time RTPCR analysis of REST4 levels (relative to actin), in
nine tumors represented in the microarray dataset GSE5460. REST4 mRNA, was detected in REST–less, but not RESTfl tumors after 35 cycles of
amplification. (C) Patients with REST–less breast tumors in the superseries GSE6532, as defined by the 24-gene signature, show a significant decrease
in their disease free survival with respect to their RESTfl counterparts (p,0.01).
doi:10.1371/journal.pgen.1000979.g005
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PLoS Genetics | www.plosgenetics.org 7 June 2010 | Volume 6 | Issue 6 | e1000979support our findings that REST function cannot be directly
measured by its mRNA levels in breast tumor oligonucleotide
arrays. However, the development of a gene signature for loss of
REST in vitro allowed for the identification of a class of REST–less
breast tumors. Analysis of tumors so characterized showed that
REST was aberrantly spliced to generate the REST4 truncated
variant. REST4 was originally identified in the hippocampii of
mice after kainic acid induced seizures [23] and results in the
inclusion of an alternative exon (exon ‘N’ which is 62 bp in
humans) between exons V and VI of the REST transcript that
encoded a stop codon and places the downstream mRNA out of
frame. REST4 transcript is therefore 62 bp longer than REST
transcript but REST4 protein possesses only 5 of the 8 zinc fingers
in the DNA binding domain and lacks the C-terminal repression
domain [6,23]. The conversion of REST to REST4 in the
hippocampus was associated with de-repression of the REST
target gene BDNF.
Importantly, REST4 splicing is regulated by cell signaling
pathways and in the case of seizure models, the alternative splicing
of REST occurs within a limited time window before full-length,
functional REST transcript splicing is restored. Indeed, in SCLC
cell lines reintroduction of full-length REST induces apoptosis.
Similarly, reintroduction of full-length REST into REST–less
colon cancer cell lines restores anoikis, blocking anchorage-
independent cell growth [14]. Therefore, we believe that the
signaling pathways regulating potentially reversible REST4
splicing represent an attractive pharmacological opportunity for
combating REST–less breast cancer.
Figure 6. Testing the specificity of the REST C-terminal antibody. (A) MCF7 breast cancer cells were infected with lentivirus bearing either
non-targeting control shRNA or REST targeting shRNA. REST knockdown was verified by western blot (Millipore antibody). Beta actin expression in
shown as a loading control. (B) Paraffin-embedded MCF7 sections were stained with antibody to the REST C-terminus (Sigma) (stained brown), with
hemetoxylin nuclear stain (stained blue). Control shRNA expressing cells show strong nuclear REST staining, while REST shRNA expressing cells show
little to no nuclear REST staining.
doi:10.1371/journal.pgen.1000979.g006
Figure 7. Immunohistochemical screen for functional REST in breast tumors. (A,B) Paraffin embedded breast tumor sections were
immunohistochemically labeled with an antibody to the C-terminus of REST. Inset image is enlarged 2.56to show detail. (A) Strong nuclear REST
labeling in the majority of tumor cells (brown signal). (B) Weak or absent labeling for REST in REST–less tumor. (C,D) Paraffin embedded breast tumor
sections were stained for the protein product of the REST target gene chromogranin-A (CHGA). (C) No CGA labeling detected in RESTfl tumor (blue
hematoxylin stain highlights nuclei of carcinoma and stroma cells). (D) Moderate to strong labeling for CGA in a subset of carcinoma cells. The brown
label (CGA) does not co-localize with the nuclear hematoxylin counterstain, suggesting a non-nuclear location. REST–less tumors were significantly
enriched in chromogranin-A staining (D, p,0.001).
doi:10.1371/journal.pgen.1000979.g007
REST Is Lost in Aggressive Breast Cancer
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To better understand the disease course taken by REST–less
tumors we took advantage of the fact that REST4 lacks the C-
terminus. This allowed us to verify loss of full-length REST via an
immunohistochemical screen utilizing an antibody raised to the C-
terminus of REST, which will not detect REST4, degraded
REST, or any previously characterized truncated mutant of
REST. IHC on a panel of 182 tumor samples with associated
outcome data showed that patients with REST–less tumors
experience a 20% reduction in disease free survival when
compared to their RESTfl counterparts over 10 years
(Figure 8A). The majority of the outcome disparity between
patients with REST–less and RESTfl tumors occurs in the first
three years post-diagnosis in REST–less tumors identified by
either the gene signature or IHC method. In both cases, at least
50% of patients with REST–less tumors showed recurrence within
three years. By comparison, less than 20% of patients with RESTfl
tumors showed recurrence within three years in both datasets
examined. Tumors that stain negative for the REST C-terminus
correlate strongly with decreased time to disease recurrence,
increased tumor size, and a higher number of lymph node
metastases, all of which indicate a more aggressive disease course
(Table 1).
Remarkably, a subset of tumors from all histological classes of
breast cancer stained negative for REST C-terminus, and all
classes showed a worse prognosis without REST. REST–less triple
negative tumors showed a particularly aggressive disease course.
Of the 32 triple negative tumors screened, 13 were found to be
REST–less, six (46%) of which recurred in the first 12 months
post-diagnosis, compared to just 1 of the 19 (5%) RESTfl triple
negative tumors (p=0.003). However, no triple negative REST–
less tumor recurred after 12 months in 10 years of patient outcome
data. ER+ REST–less tumors showed a similar pattern of early
recurrence, wherein 8 of 21 (38%) patients saw disease recurrence
in the first 36 months, compared to just 11% of ER+ RESTfl
patients (p=0.003). Thereafter, none of the remaining 13 disease-
free patients with ER+ REST–less tumors experienced recurrence,
compared to 12 of the 102 remaining disease-free ER+ RESTfl
patients. These data suggest that REST–less tumors represent a
distinct, aggressive subset of breast tumors with a unique disease
course.
In their recent paper, Reddy et al. examine REST levels in 19
samples of normal and neoplastic breast tissues. Using 3 control
tissue samples and 16 tumors spread among 3 tumor stages, they
suggest that REST protein and mRNA levels undergo a stepwise,
statistically significant decrease with each increasing tumor stage
[28]. We examined gene expression in over 250 samples of tumor
and normal tissue in three different publicly available databases
and find that breast tumors express REST mRNA at levels at or
above those in normal tissue. We did not find a single tumor with
REST mRNA levels lower than that of the control tissue. After
further analysis of over 700 additional tumors of varying grade,
stage, and eventual recurrence, we find that REST mRNA levels
are invariant with any of these conventional measures of tumor
aggression (Figure 4C). Reddy et al. reported that they did not
observe any alternate splice variants in the tumor samples in which
they find REST to be lost (Reddy et al.– data not shown).
However, we have found alternative REST splicing in tumors
where REST function is lost (Figure 5). The reason for these
discrepancies is not clear at this time, but understanding the
Figure 8. Outcome data for patients with REST–less and RESTfl
breast tumors. (A) Patients with REST–less breast tumors show
significantly decreased disease free survival time (p=0.007, n=182),
and increased incidence of relapse (p=0.054, n=182), particularly in
the first three years post diagnosis. (B) Patients with REST–less estrogen
receptor/progesterone receptor/HER2 negative (TrpNeg) breast cancer
show a similar pattern of high tumor aggression in the first year post-
diagnosis, relative to their RESTfl counterparts. (C) Patients with REST–
less estrogen receptor (ER) positive tumors show high levels of disease
aggression in the first 3 years post diagnosis.
doi:10.1371/journal.pgen.1000979.g008
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understanding its role in the disease, and thus should be based on
robust and consistent data.
Breast cancer is a heterogeneous disease, with histologically
identical tumors often displaying very different disease courses and
responses to treatment. Unsupervised hierarchical clustering of
breast tumors based on their transcriptional profiles has uncovered
at least five unique subtypes of breast cancer [29–31]. Addition-
ally, at least two different gene signature based molecular
diagnostics (Oncotype DX and Mammaprint) are currently in
use clinically to help physicians and patients predict risk of
metastasis and response to treatment [32]. Importantly, the 24-
gene REST gene signature does not have any genes in common
with any of the above genesets, and is unique in that the cause of
the gene signature is known. Understanding the origin of this
unique breast cancer subtype is important, as it may lead to the
development of REST-targeted therapies.
In summary, we show here that REST–less tumors represent a
distinct, aggressive subset of breast tumors with a unique disease
course. We find that the REST–less gene signature is closely
associated with the presence of the truncated REST4 splice variant
and that REST status is an important predictor of poor prognosis
that correlates with increased lymph node metastasis and early
disease recurrence.
Materials and Methods
Cell culture conditions
All cells were grown in 5% CO2 at 37uC. HEK-293 and MCF7
cells were grown in DMEM with 4.5 g/L glucose, 2 mM L-
Glutamine, and 10% fetal bovine serum from HyClone (Logan,
UT). T47D cells were grown in RPMI with L-glutamine, 10 ug/
mL insulin, and 10% fetal bovine serum. MCF10a cells were
grown in DMEM/F12 with 5% horse serum, 10 mg/mL
insulin, 20 ng/mL epidermal growth factor, and 0.5 mg/mL
hydrocortisone.
Lentiviral knockdown
Stable REST knockdown in HEK-293, T47D and MCF10a
cells for microarray analysis was achieved using a Dharmacon
SMARTvector lentiviral shRNA delivery system as per manufac-
turer’s instructions. Briefly, cells were infected in the presence of
8 mg/mL polybrene at an MOI of 5 with virus expressing a non-
targeting control or REST shRNA. Puromycin selection was
begun 48 hours after infection and maintained during cell
expansion and experimentation. SMARTvector Lentiviral Parti-
cles (catalog #SH-042194-01-25) towards REST targeted the
sequence GCAAACACCTCAATCGCCA, Non-Targeting
SMARTvector shRNA Lentiviral particles (catalog #S-005000-
01) were used as an infection control.
Microarray data generation and processing
RNA was extracted using TRIzol (Invitrogen) as per the
manufacturer’s instructions from four independent plates of each
cell line T47D, HEK-293 and MCF10a, with two biological
replicates of cells expressing REST shRNA and another two
biological replicates expressing a non-targeting control shRNA.
All RNA reverse transcription, amplification and hybridizations
were performed by the University of Wisconsin-Madison Gene
Expression Center (http://biotech.wisc.edu/GEC/). RNA integ-
rity and quality were assessed by comparing 28S/18S rRNA ratio
using Agilent RNANano6000 chips on an Agilent 2100 Bioana-
lyzer. First and second strand cDNA synthesis steps, followed by in
vitro transcription, were performed using the Ambion Amino Allyl
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to the aRNA, with each fluorophore labeling a separate biological
replicate, before fragmentation and dual hybridization to Nimble-
gen HG18 60mer 385k Gene Expression Arrays (Nimblegen, Cat
#A4542-00-01). For dual hybridization, shControl and shREST
samples from the same cell line were competitively hybridized.
Arrays were scanned on an Axon4000B and the gene expression
data was extracted, and RMA normalized using software provided
by Nimblegen.
Bioinformatic analyses on the microarray data were performed
using BRB-ArrayTools v3.7 (developed by Dr. Richard Simon and
BRB-ArrayTools Development Team) and MultiExperiment
Viewer 4.5.1. Tumor gene expression data were obtained from
the NCBI Gene Expression Omnibus, and are identified by their
GEO dataset record number. Dataset E-TABM-276 was down-
loaded from the Ensembl ArrayExpress. Analysis of dataset
GSE6532 was performed to determine the aggressiveness of
tumors identified as being REST–less using the gene signature
method. All samples from this dataset that included information
on duration of relapse free survival as well as relapse event
information were included in our analysis, for a total of 206
outcome-associated tumors. Hierarchical clustering was performed
using a one-minus correlation metric with average linkage over
centered genes. Cluster diagrams were produced using BRB
Arraytools, Cluster 3.0 and TreeView software. Class comparison
analysis between REST–less and RESTfl tumors was performed
using a random variance model for univariate tests with a
significance threshold of p,10
27 to reduce false positives.
Gene Set Enrichment Analysis (GSEA) was performed using the
GSEA program provided by the Broad Institute. GSEA compares
the expression of a set of experimentally defined REST target
genes (termed ‘‘S’’) between REST–less and RESTfl tumors, and
assesses the relative enrichment of S in either tumor group. The
positive enrichment scores obtained from these analyses are
indicative of high level enrichment of REST target gene
expression in the REST–less tumor subset. To determine whether
this enrichment could arise by random chance, 1,000 permuta-
tions of the above analysis were performed with each permutation
randomly assigning tumors as being either REST–less or RESTfl
and then assessing enrichment in each group for S. The fraction of
permutations that result in an enrichment for REST target genes
in the randomly assigned ‘‘REST–less’’ tumor group serves as an
estimate of statistical significance and is presented as a nominal p-
value (Subramanian et al.PNAS 2005). Similarly, the false
discovery rate (FDR) q-value is a measure of the likelihood that
a geneset S may be a false positive, but this statistic is controlled for
gene set size and may therefore be compared between multiple
genesets with normalized enrichment scores. The list of REST
target genes identified in the Johnson et al. ChIP-Seq were chosen
on the basis of their enrichment in both experiments 1 and 2 in a
region carrying an RE1 site with a p-value of ,10
24. Genesets
used in GSEA analysis are available as Table S3.
Amplifying REST4 from tumor RNA
The work with human tumor RNA was found to be exempt
from institutional review by the UW institutional review board
(IRB). Tumor RNA was amplified in duplicate according to the
Affymetrix manual on Eukaryotic Target Preparation, Section 2.1
(https://www.affymetrix.com/support/downloads/manuals/
expression_s21_manual.pdf). Briefly, a first strand of cDNA
was generated from 100 ng of tumor RNA using T7-oligo(dT)
primers, incubated at 70uC for 10 minutes, followed by 2
minutes on ice. A first-strand reaction mix with dNTPs, DTT
and SuperScript III Reverse Transcriptase (Invitrogen) was
added to each sample and incubated for an hour at 42uC,
then transferred to ice. The second strand of cDNA synthesis
was performed using a second-strand reaction mix, dNTPs,
E. coli DNA ligase, E. coli DNA polymerase, and RNase H,
and was incubated at 16uC for 2 hours. T4 DNA polymerase
was added for the final 5 minutes of this incubation period,
generating full-length double-stranded cDNA. The cDNA
was purified on MinElute PCR purification columns (Qiagen)
as per manufacturer’s instructions. The Megascript T7 RNA
polymerase kit (Ambion) was used to generate aRNA from
the tumor cDNA as per the manufacturer’s instructions. The
aRNA was purified from the reaction mix using Trizol
(Invitrogen) as per the manufacturer’s instructions, and
500 ng of tumor aRNA was used to generate tumor cDNA
using SuperScript III RT Kit (Invitrogen) as per manufac-
turer’s instructions. This cDNA then served as a template for
the PCR amplification of REST using Pfx Platinum high
fidelity polymerase (Invitrogen) as per manufacturer’s in-
structions.
Quantitative real-time PCR analysis of REST 4 was performed
using a 5 ng aRNA equivalent of cDNA, the SYBR qRT-PCR
System (Takara) and hREST4 Forward and hREST SV Region
Reverse primers over 35 cycles.
Primers used to amplify the exon junctions surrounding introns
1 and 2:
hREST SV region forward: GAGCGAGTATCACTGGAG-
GAAACATTT
hREST SV region reverse: ATAGTCACATACAGGG-
CAATTGAACTGC
Primers used to amplify REST4:
hREST4 forward (Used with hREST SV reverse): CATT-
CAGTGGGGTATGGATACC
hREST4 reverse (Used with hREST SV forward):
GCTTCTCACCCATCTAGATCAC
Immunohistochemistry on tissue microarray and
outcome analysis
Four-micron sections of previously characterized tissue micro-
arrays, which contain duplicate tissue cores from 207 human
breast carcinomas, were used for the labeling experiments [33].
Chromogranin A labeling was performed on an automated
Ventana instrument (Ventana Medical Systems, Tucson, AZ).
After a standard deparaffinization procedure, epitope retrieval was
performed with CC1 high-pH buffer (Ventana). In the automated
protocol, the prediluted anti-chromogranin A antibody (Clone
LK2H10, Ventana) was added for 32 minutes at 42uC. After
addition of a universal secondary antibody, target detection was
accomplished with an indirect biotin-avidin-peroxidase procedure.
Labeling for REST was performed on a Lab Vision Autostainer
360. After deparaffinization, heat-induced epitope retrieval with
citrate buffer and endogenous peroxidase inhibition, the slides
were blocked with Background Sniper (Biocare Medical). The
sections were then incubated with rabbit anti-REST antibody
(HPA006079, Sigma-Aldrich) at a concentration of 0.5 mg/ml for
60 minutes. After washing, the Mach 3 detection system (Biocare
Medical) was applied. The labeling reaction was manually scored
by a board-certified pathologist (AF) for the cytoplasmic and
nuclear carcinoma cell compartments, using the method described
by Harvey and colleagues [34].
Kaplan Meier plots were generated using SigmaStat 3.0, and
Kaplan Meier curves were compared using the logrank test. We
report as significant only those curves that have reached a level of
p#0.05. Correlations between REST status and disease param-
REST Is Lost in Aggressive Breast Cancer
PLoS Genetics | www.plosgenetics.org 11 June 2010 | Volume 6 | Issue 6 | e1000979eters were tested using Pearsons Chi-squared test, and are reported
as significant p#0.05.
Supporting Information
Table S1 This table lists genes that show a .2 fold upregulation
following REST knockdown, as determined by oligonucleotide
microarray in 3 cell lines: HEK-293, MCF10a, and T47D cells.
Found at: doi:10.1371/journal.pgen.1000979.s001 (0.10 MB
XLS)
Table S2 This table describes the gene list determined to be
associated with RESTless tumors in dataset GSE5460 by class
comparison. This list of genes represents all of the genes identified
as more highly expressed in RESTless tumors with respect to
RESTfl tumors in the GSE5460 dataset (p,e-7) by using a
random variance model for univariate tests in BRB Arraytools
v3.7. Of the 72 genes in this list, 63 are putative REST targets, as
defined by a consensus RE1, positive ChIP Seq signal, or a two-
fold change upon REST knockdown in at least one of three cell
lines.
Found at: doi:10.1371/journal.pgen.1000979.s002 (0.08 MB
XLS)
Table S3 This table provides the gene sets used in gene set
enrichment analysis of dataset GSE5460.
Found at: doi:10.1371/journal.pgen.1000979.s003 (0.06 MB
XLS)
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